Recombinant Human Interferon lambda-3(IFNL3)

Code CSB-YP810313HU
Size Pls inquire
Source Yeast
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP810313HU
Size Pls inquire
Source E.coli
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP810313HU-B
Size Pls inquire
Source E.coli
Conjugate Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-BP810313HU
Size Pls inquire
Source Baculovirus
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-MP810313HU
Size Pls inquire
Source Mammalian cell
Have Questions? Leave a Message or Start an on-line Chat

Product Details

>85% (SDS-PAGE)
Target Names
Uniprot No.
Alternative Names
Cytokine ZCYTO22; IFN-lambda-3; IFN-lambda-4; IL-28B; IL-28C; IL28B; IL28B_HUMAN; IL28C; Interferon lambda-3; Interferon lambda-4; interleukin 28B (interferon; lambda 3); Interleukin 28C; Interleukin-28B; Interleukin-28C
Homo sapiens (Human)
Expression Region
Target Protein Sequence
Protein Length
Full Length of Mature Protein
Tag Info
The following tags are available.
N-terminal His-tagged
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer before Lyophilization
Tris/PBS-based buffer, 6% Trehalose, pH 8.0
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression.
Gene References into Functions
  1. No association between IFNL3 genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B patients was found. PMID: 30016335
  2. When analyzing the frequency of occurrence of a polymorphic variant T>G [rs8099917] IL-28B gene in children with chronic hepatitis C and healthy children revealed no differences in the distribution of alleles. PMID: 30284423
  3. zinc can act as a potent and specific inhibitor of IFN-lambda3 signaling. PMID: 28513591
  4. IL28B and MxA gene genotypes were detected among 231 chronic hepatitis C (CHC) carriers, 428 subjects with hepatitis C virus spontaneous clearance and 662 CHC patients with pegylated IFN-alpha and ribavirin (pegIFN-alpha/RBV) treatment. PMID: 29271328
  5. Single nucleotide polymorphisms (SNPs) rs12979860 and rs8099917 (IL28B) and rs1800896, rs1800871, and rs1800872 (IL10) are related to treatment outcome, but previous studies clustered nonresponse and relapse patients.Frequency of rs12979860 and rs8099917 is different between relapsers and nonresponders, but similar between relapsers and responders PMID: 29888255
  6. only IL28B rs12979860-CT and TT genotypes seem to contribute to the occurrence of chronic HCV infection in the cohort of Uruguayan population studied. Considering that a trend towards a higher frequency of "good" response genotypes was observed in responder patients, we believe that IL28B rs12979860 genotyping could be a useful tool for predicting different therapies outcome, including in the DAA era. PMID: 29499724
  7. our data show a significant association between rs12979860 polymorphism and hematologic response to IFN-alpha in PV and in the combined cohort of PV and ET. These findings imply that inborn variations in the genes involved in inflammation are related to the outcome of IFN-alpha treatment in MPNs. PMID: 29369421
  8. The selected donor with a predictable and favourable IL-28B genotype will not confer a benefit on the recipient in the living donor liver transplantation setting. PMID: 29686997
  9. IL-28B polymorphisms may be useful predictive factors for chronic periodontitis (CP) and correlated to the susceptibility to CP infection. PMID: 28655358
  10. IL28B rs12979860 polymorphism does not influence the susceptibility to HIV-1 and the AIDS development in Moroccan patients, however, this polymorphism may affect the response to HAART treatment as measured by CD4+ T cell counts PMID: 29080719
  11. This is the first report on a diagnostic test for simultaneous genotyping of IFNL3, ABCB11, and RNF7 in Chronic hepatitis C (CHC) patients. Reliable and inexpensive, the assay should provide useful information for the clinical management of CHC, like identification of patients at risk of rapid disease progression or with high chances of response to classic therapy. PMID: 28860020
  12. Results showed that INF-lambda serum concentration was increased in Alzheimer's disease (AD) and mild cognitive impairment (MCI) carrying the IFNL3 T allele compared to healthy controls (HC). Anti-HSV-1 Ab titers were higher in AD and MCI individuals carrying the IRF7 AA genotype compared to HC. IFNL3 rs12979860 and IRF7 rs6598008 polymorphisms may modulate immune responses against HSV-1 via their effect on the IFN-lam... PMID: 28984602
  13. Regardless of viral genotype we found no association between IL28B genotype and the risk of vertical transmission of HCV. The IL28B genotype CC, which has been shown to be favourable in other settings, was not protective of vertical transmission of HCV. PMID: 28820758
  14. The authors concluded that in the Chinese population, HLA-A*02:01 and DRB1*11:01 might be associated with the host capacity to clear hepatitis C virus independent of IL28B, which suggests that the innate and adaptive immune responses both play an important role in the control of hepatitis C virus. PMID: 27511600
  15. In a cohort of patients affected by HCV chronic hepatitis with genotypes 1 and 4, the prevalence of interleukin 28B (IL28B) genotypes, the possible association between IL28B polymorphism and severity of liver damage, the role of IL28B CC as a predictor of outcome were investigated PMID: 27271956
  16. Fine-tuned by RETN SNPs, intrahepatic, multi-cellular resistin reinforced IFNL3 in eliminating HCV via immunomodulation to counteract pro-inflammation. PMID: 27477870
  17. Investigated the associations of IL-28B rs12979860 and TBX21 rs17250932, rs4794067 polymorphisms with the susceptibility to, and outcomes of, hepatitis C virus (HCV) infection; results showed no significant associations for rs12979860 polymorphisms with HCV clearance and sustained virological response PMID: 29399747
  18. IFNL3 rs4803217 SNP is a strong, independent and superior predictor of sustained virological response and relapse in HCV genotype 1 infected chronic hepatitis C patients treated with pegylated interferon alpha and ribavirin. PMID: 28638221
  19. IL-28B single nucleotide polymorphism rs8099917TT is the most frequent genotype in Cuban chronic hepatitis C patients and is associated with treatment outcome as well. PMID: 28058039
  20. Liver stiffness progression in patients with chronic hepatitis C virus correlated with the IL28B TT/CC and IL28B GG/TT genotypes. PMID: 28579527
  21. IL28B (rs8099917 and rs12979860) and IL10 (rs1800896) polymorphisms alone, or in combination, are good predictors of therapeutic response in hepatitis C virus-3a patients. PMID: 29340806
  22. In this study, limit of detection (LD), costs and turnaround time of these methods were compared in 350 subjects. As for IL28B rs12979860 polymorphisms, 348/350 (99.4%) samples were consistent among the five methods, while results for 2/350 (0.57%) samples were concordant by ZNAs and PCR-sequencing, and discordant by other methods PMID: 28281380
  23. Of the 1084 patients with the IL-28 genotype, 59.4% had hepatitis C virus genotype 1 (HCV-1) infection; 85.6% had the TT genotype. Patients with advanced liver fibrosis had an older age, a lower platelet count, a higher [alpha]-fetoprotein level, a higher alanine aminotransferase level, a higher incidence of diabetes, and a higher frequency of rs8099917 non-TT genotype carriage. PMID: 29517696
  24. The SNP distribution of gene IL28 with fixed prognostic value in the population of patients with chronic hepatitis C is different from the general population, and shows the need to evaluate polymorphisms prior to treatment. PMID: 29264884
  25. Polymorphisms of IFNL3 rs8099917 and IL12A rs568408 contribute to survival of HD patients, but not as independent factors. PMID: 28525983
  26. Both hepatitis C virus-specific T cell responses and IL28B rs12979860 single-nucleotide polymorphism genotype influence anti-hepatitis C virus treatment outcome in patients with chronic hepatitis C. PMID: 28440692
  27. IFNL3 SNPs are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. PMID: 28703131
  28. TLR2 and IL28B polymorphisms in combination showed a role in the control of HCV viral load and different HCV disease progression. PMID: 27183918
  29. These findings indicate that serum IFNL3 levels at baseline are higher in acute hepatitis C patients regardless of the rs8099917 polymorphism, and primary hepatitis C virus infection triggers the production of IFNL3. PMID: 29040985
  30. The association between IFNL3/4 genotypes with elevated HCV VL observed in HCV g6-infected individuals may have implications for the progression of liver disease in Southeast Asian countries where this viral genotype predominates and therefore warrants further studies. PMID: 29022122
  31. In summary, the current study did not find a significant association between IL28B rs12979860 polymorphism and hepatocarcinogenesis. PMID: 27083168
  32. Interferon lambda polymorphisms influence regulatory pathways of cellular response to interferon and affect body iron balance in chronic hepatitis C virus infection. PMID: 27125837
  33. IL-28B rs12979860 SNP could be used as an independent predictor for treatment response among HCV patients. PMID: 28502145
  34. In hemodialysis patients, circulating IFN-lambda3 strongly correlates with anti-HBs antibody production after HBV vaccination and infection. IFNL3 rs8099917 polymorphisms seem to be associated with IFN-lambda3 plasma levels in hemodialysis subjects. PMID: 27595449
  35. Results demonstrated genetic variations of IL-28B might impact liver function recovery after transplantation by influencing peripheral platelet counts and reducing liver inflammation, but weak association with transplant etiologies. PMID: 29095252
  36. The results obtained suggest that both studied IL28B gene SNPs (single nucleotide polymorphisms), as well as the IL10 gene rs1800872 SNP are associated with predisposition to tick-borne encephalitis in Russian population. PMID: 27068548
  37. IL-28B genotyping may be useful for directing patients towards lower cost therapies, and rationing use of costly direct antivirals for use in those individuals showing genetic risk. PMID: 28877177
  38. the IFNL3 rs 12979860 CC genotype may be negatively associated with hepatic steatosis in Asian chronic hepatitis C patients. PMID: 28797039
  39. IL-28B rs12979860 genotype was significantly related to severe necroinflammatory activity (NIA) grade of chronic hepatitis C patients. PMID: 28704535
  40. Data show that the genotype distributions of IFNL3 and IFNL4 variants (rs4803217, rs368234815, rs117648444, and rs12979860) were in Hardy-Weinberg equilibrium. PMID: 28394349
  41. In summary, the data suggested that the protective effect attributed to the rs12979860 single nucleotide polymorphism minor T allele could be mediated, at least in part, by eliciting robust cytomegalovirus-specific T-cell responses. PMID: 27591738
  42. The data confirm our new IFN-lambda3 binding assay can be used to quantify IFN-lambda receptor surface expression on a variety of cell types and reflects IFN-lambda3 responsiveness. PMID: 28274837
  43. In Taiwan, chronic hepatitis C (CHC) patients have a lower frequency of favorable IL28B TT genotype than healthy controls. Among patients with CHC, the frequency of TT genotype is higher in HCV genotype 2 patients than in HCV genotype 1 patients. In addition, CHC patients with TT genotype, particularly females, have a lower likelihood of advanced fibrosis. PMID: 27751759
  44. IFNL3 SNPs genotyped have shown no association with ribavirin treatment in hepatitis C patients with genotype 3. PMID: 27498543
  45. in influenza A/H3N2 virus infection, IL-28 (rs8099917) genotypes GG and TG were associated with reduced risk of influenza like illness (ILI) symptoms while genotype TT was associated with increased risk of ILI symptom PMID: 27155288
  46. monocytes from carriers of an IL-28B T/T genotype display a reduced ability to stimulate NK cell activity PMID: 27583440
  47. alterations in IL28B SNP genotype may occur after living donor liver transplantation, leading to modifications in the host genome or donor proteome by HCV. PMID: 27275739
  48. Results show that detection of SNPs in IL28B combined with increased IP-10 levels increase predictability of sustained virological Response in patients treated with pegylated interferon 2alpha a plus ribavirin. PMID: 26470765
  49. In patients infected with HCV-3 [hepatitis-C virus genotype-3], IFNlambda3 [interferon lambda-3] rs12979860, SNP[ single nucleotide polymorphisms ] has less impact on SVR [sustained virologic response ]. PMID: 27353984
  50. the association of amino acid substitutions in the HCV core protein and the IFNL3 and IFNL4 polymorphisms with the severity of liver disease, particularly in hepatocellular carcinoma development PMID: 27035616

Show More

Hide All

Subcellular Location
Protein Families
Lambda interferon family
Database Links

HGNC: 18365

OMIM: 607402

KEGG: hsa:282617

STRING: 9606.ENSP00000409000

UniGene: Hs.406744

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1